Helius Medical TechnologiesHSDT
HSDT
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
214% more capital invested
Capital invested by funds: $45.3K [Q3] → $142K (+$96.9K) [Q4]
36% more funds holding
Funds holding: 14 [Q3] → 19 (+5) [Q4]
3.48% more ownership
Funds ownership: 2.26% [Q3] → 5.74% (+3.48%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for HSDT.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius' existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development-- --Helius to Present at the 37 th Annual ROTH Conference on Monday, March 17 at 12:00pm PT-- NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for improving balance and gait deficits and reducing the risk of falling, today announced the establishment of Revelation Neuro, Inc. (“Revelation Neuro”), its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology.
Neutral
GlobeNewsWire
2 weeks ago
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
--Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its PoNS Device.
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1 to 5.9, p
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced today announced it has entered into agreements with certain holders of its existing warrants exercisable for 4,971,110 shares of its common stock, in the aggregate, to exercise outstanding warrants at a reduced exercise price of $0.751 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $3.7 million, before deducting financial advisory fees. The exercisability of the new warrants and any resulting issuance of the shares underlying the new warrants are subject to stockholder approval in accordance with Nasdaq rules.
Neutral
GlobeNewsWire
3 months ago
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
Initial order placed with Company's distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract Initial order placed with Company's distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract
Neutral
GlobeNewsWire
4 months ago
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.
Positive
MCAP MediaWire
5 months ago
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.
Neutral
GlobeNewsWire
5 months ago
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.
Neutral
GlobeNewsWire
5 months ago
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle --
Neutral
GlobeNewsWire
7 months ago
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August 14, 2024, its independent directors approved equity awards under Helius' 2021 Inducement Plan, as a material inducement to three individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
Charts implemented using Lightweight Charts™